Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ellen Van Damme

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
The Journal of General Virology|July 15, 2016
Human cytomegalovirus miR-UL112-1 promotes the down-regulation of viral immediate early-gene expression during latency to prevent T-cell recognition of latently infected cellsBetty Lau, Emma Poole, Ellen Van Damme, et al.
Plos One|April 24, 2014
A method enabling high-throughput sequencing of human cytomegalovirus complete genomes from clinical isolatesSteven Sijmons, Kim Thys, Michaël Corthout, et al.
Journal of Medical Virology|March 5, 2021
In vitro activity of itraconazole against SARS-CoV-2Ellen Van Damme, Sandra De Meyer, Denisa Bojkova, et al.
Journal of Virology|May 15, 2015
High-throughput analysis of human cytomegalovirus genome diversity highlights the widespread occurrence of gene-disrupting mutations and pervasive recombinationSteven Sijmons, Kim Thys, Mirabeau Mbong Ngwese, et al.
Antiviral Research|February 11, 2026
Optimal preclinical models for human dose projection of SARS-CoV-2 small molecule direct-acting antiviralsFrancesca Toselli, Sofie Jacobs, Els Scheers, et al.
Journal of Medical Virology|March 1, 2022
Development and optimization of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity: Evaluation of 5676 Phase 1 Passed StructuresWinston Chiu, Lore Verschueren, Christel Van den Eynde, et al.
Antiviral Research|December 29, 2023
A flexible, image-based, high-throughput platform encompassing in-depth cell profiling to identify broad-spectrum coronavirus antivirals with limited off-target effectsJordi Doijen, Inha Heo, Koen Temmerman, et al.
Journal of Computational Chemistry|September 5, 2025
A New Fragment-Based Pharmacophore Virtual Screening Workflow Identifies Potent Inhibitors of SARS-CoV-2 NSP13 HelicaseJordi Doijen, Jiexiong Xie, Simone Marsili, et al.
Microorganisms|March 29, 2023
Identification of Z-Tyr-Ala-CHN<sub>2</sub>, a Cathepsin L Inhibitor with Broad-Spectrum Cell-Specific Activity against Coronaviruses, including SARS-CoV-2Jordi Doijen, Koen Temmerman, Christel Van den Eynde, et al.
Communications Biology|November 25, 2025
Structural insights into MERS and SARS coronavirus membrane proteinsMandeep Kaur Mann, Yanting Yin, Simone Marsili, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
The Journal of General Virology|July 15, 2016
Human cytomegalovirus miR-UL112-1 promotes the down-regulation of viral immediate early-gene expression during latency to prevent T-cell recognition of latently infected cellsBetty Lau, Emma Poole, Ellen Van Damme, et al.
Plos One|April 24, 2014
A method enabling high-throughput sequencing of human cytomegalovirus complete genomes from clinical isolatesSteven Sijmons, Kim Thys, Michaël Corthout, et al.
Journal of Medical Virology|March 5, 2021
In vitro activity of itraconazole against SARS-CoV-2Ellen Van Damme, Sandra De Meyer, Denisa Bojkova, et al.
Journal of Virology|May 15, 2015
High-throughput analysis of human cytomegalovirus genome diversity highlights the widespread occurrence of gene-disrupting mutations and pervasive recombinationSteven Sijmons, Kim Thys, Mirabeau Mbong Ngwese, et al.
Antiviral Research|February 11, 2026
Optimal preclinical models for human dose projection of SARS-CoV-2 small molecule direct-acting antiviralsFrancesca Toselli, Sofie Jacobs, Els Scheers, et al.
Journal of Medical Virology|March 1, 2022
Development and optimization of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity: Evaluation of 5676 Phase 1 Passed StructuresWinston Chiu, Lore Verschueren, Christel Van den Eynde, et al.
Antiviral Research|December 29, 2023
A flexible, image-based, high-throughput platform encompassing in-depth cell profiling to identify broad-spectrum coronavirus antivirals with limited off-target effectsJordi Doijen, Inha Heo, Koen Temmerman, et al.
Journal of Computational Chemistry|September 5, 2025
A New Fragment-Based Pharmacophore Virtual Screening Workflow Identifies Potent Inhibitors of SARS-CoV-2 NSP13 HelicaseJordi Doijen, Jiexiong Xie, Simone Marsili, et al.
Microorganisms|March 29, 2023
Identification of Z-Tyr-Ala-CHN<sub>2</sub>, a Cathepsin L Inhibitor with Broad-Spectrum Cell-Specific Activity against Coronaviruses, including SARS-CoV-2Jordi Doijen, Koen Temmerman, Christel Van den Eynde, et al.
Communications Biology|November 25, 2025
Structural insights into MERS and SARS coronavirus membrane proteinsMandeep Kaur Mann, Yanting Yin, Simone Marsili, et al.
Pageof 3